Home > Newsletters > FDAnews Drug Daily Bulletin > EC Cracks Down on ‘Pay-for-Delay,’ Charging Slew of Generic Makers
FDAnews Drug Daily Bulletin
Aug. 3, 2012 | Vol. 9 No. 152
EC Cracks Down on ‘Pay-for-Delay,’ Charging Slew of Generic Makers
The European Commission (EC) has accused two brand drugmakers of violating antitrust rules by engaging in “pay-for-delay” agreements with a slew of generic companies, sending both the brand and generic companies Statement of Objections notices. The charges could cost involved companies up to 10 percent of their annual worldwide turnover, the EC says. According to the EC, Danish drugmaker Lundbeck provided substantial transfers of value, including direct payments, to the generic companies in exchange for keeping copycats of blockbuster antidepressant Celexa (citalopram) off the EU market.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.